PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants

PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants Gary Kohanbash, Scott Ryall, Sam E. Gary, Lindsey M. Hoffman, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8662616/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Mar, 2026 Read the published version in Journal of Neuro-Oncology → Version 1 posted 15 You are reading this latest preprint version Abstract Purpose: To characterize the clinical, radiological, and molecular characteristics of CNS tumors associated with Noonan syndrome (NS) and other non-Neurofibromatosis type 1 RASopathies. Methods: Twenty-four patients with concern for NS underwent clinical and central radiological review in this multi-institutional study. Whole-exome sequencing, RNA sequencing, and methylation analyses of peripheral blood and/or tumor specimens were performed. Results: Nineteen (79%) of 24 participants had NS, 17/19 (89%) of which had a germline PTPN11 variant; Nineteen of 24 participants (79%) were male. Seventeen (89%) patients with NS developed CNS cancers, including low-grade glioma, (LGG; pure pilocytic/pilomyxoid astrocytoma; n =9) and mixed dysembryoplastic neuroepithelial tumor (DNET; n =6). Five patients incidentally diagnosed did not undergo histological confirmation. Radiological review showed multifocal parenchymal tumors in 9 patients with NS, including histologically confirmed neoplasm ( n =2), radiologic progression ( n =6), or typical tumoral imaging ( n =1). All LGGs in patients with NS and germline PTPN11 variants except one (14/15; 93%) harbored somatic FGFR1 abnormalities. RNA sequencing of 12 tumors detected FGFR1 internal tandem duplication in one patient. Comparison with published data showed a statistically significant association between brain tumor occurrence and PTPN11 -related NS, driven by two genotypes: NM_002834.5(PTPN11):c.182A>G (p.Asp61Gly) and c.417G>T (p.Glu139Asp). Ten patients with LGGs, including 7 (41%) with NS, required chemotherapy. After median follow-up of 7.5 years, one patient died of CNS cancer. Conclusion: PTPN11 -related NS predisposes to multifocal pure and mixed LGGs confirmed by radiological, histological, and molecular characteristics. Targeting FGFR1-related pathways may provide new treatment approaches for patients with NS and LGGs. Brain tumor glioma Noonan syndrome PTPN11 FGFR1 Figures Figure 1 Figure 2 Figure 3 Key points Multifocal low-grade glial and glioneuronal tumors are common in patients with Noonan syndrome, especially in males. Concurrent PTPN11 and FGFR1 variants exist in nearly all patients with Noonan syndrome and LGG. Targeting FGFR1may provide novel treatment options for patients with Noonan syndrome and LGG. Translational Relevance: Noonan syndrome (NS) has been recognized as a genetic predisposition to CNS tumors. However, no long-term clinical, radiological, or molecular patient data have previously been reported in a large patient cohort. Herein, we show that individuals with NS and germline PTPN11 variants, particularly those with NM_002834.5(PTPN11):c.182A>G (p.Asp61Gly) and NM_002834.5(PTPN11):c.417G>C (p.Glu139Asp), are predisposed to develop low-grade gliomas (LGGs; pure and mixed glioneuronal), which may have multifocal distant brain involvement in up to 50% of patients. An overwhelming male predominance was confirmed, for which the biological underpinnings remain unknown. Somatic FGFR1 variants were detected in 93% of LGGs in individuals with PTPN11 -related NS. Therefore, concurrent variants in both genes seem to be required to drive gliomagenesis. Most LGGs experienced indolent behavior, even in the presence of residual disease, and the affected patients experienced long-term survival. However, aggressive monitoring and treatment may be necessary in a subset of patients. Introduction Cancer predisposition syndromes are present in 8% to 21% of pediatric patients with central nervous system (CNS) cancers [ 1 – 3 ]. Inhibition of RAS signaling through germline abnormalities in NF1 , as well as germline abnormalities in non- NF1 RASopathies (NNFRAS), is associated with non-CNS cancers [ 4 – 6 ]. NNFRAS comprise a large and heterogenous group of disorders, the most common of which is Noonan syndrome (NS), with an incidence of up to 1:1,000 live births [ 7 , 8 ]. Multiple case reports and one case series (n = 5 patients) have described the association of NNFRAS [ 5 , 9 – 20 ], particularly NS, with low-grade glioma (LGG). However, no large-scale data exist that that characterize clinical, radiological, and molecular features driving tumorigenesis and patient outcomes [ 11 , 14 , 20 , 21 ]. Based on the prevalence of NS, the overlap between germline abnormalities found in NNFRAS and somatic changes found in pediatric CNS cancers, and our institutional experience [ 7 , 8 , 22 ], we conducted this multi-institutional study consisting of the largest reported patient population to evaluate clinical, radiological, and molecular characteristics that underlie NS and development of LGG. Leveraging this large cohort, we unveil novel, consistent associations between NS and LGG, including multifocal involvement and co-occurrence of germline PTPN11 and somatic FGFR1 abnormalities, indicating potentially new FGFR1-targeted treatment options. Material and Methods Data and sample collection. Once Institutional Review Board approval (University of Pittsburgh #19060202) was obtained at six participating institutions in the US and Australia, patients with NNFRAS and CNS cancers were recruited to this study. CNS cancers were either histologically confirmed or suspected based on imaging characteristics. Except for three deceased patients, informed consent to study participation was obtained from adult patients, parents, or legal guardians. Assent and re-consent at age of majority were obtained according to institutional standards. Clinical information consisting of demographics, characteristics of NNFRAS, diagnosis and therapy of CNS cancers, and survival were obtained from all research participants. An experienced pediatric neuro-oncologist (A.B.) performed central radiological review of pertinent scans, including MRI and CT at diagnosis and at most recent available follow-up. Whole Exome (WES) and RNA Sequencing. Germline DNA was extracted from either blood or saliva, and DNA and RNA were extracted from tumor samples, mostly derived from formalin-fixed, paraffin-embedded (FFPE) tissue, following standard methods. WES was performed at Novogene Corporation Inc. (Sacramento, CA) or at UPMC Hillman Cancer Center Core Laboratory. For WES done at Novogene, extracted DNA was quantified using Qubit TM dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA). DNA libraries were prepared using Agilent SureSelect system (Agilent Technologies, Santa Clara, CA) to capture DNA coding sequences. 400 ng of genomic DNA was processed through fragmentation, enzymatic end-repair and A-tailing, adapter ligation, RNA probe hybridization, and polymerase chain reaction (PCR) amplification. The quality of libraries was analyzed with the DNA NGS 3K Assay Kit and LabChip GX Chip (PerkinElmer, Waltham, MA). Libraries with an average size of 400 bp (range: 300–600 bp) were quantified by qPCR using the VAHTS Library Quantification Kit for Illumina (Vazyme, Nanjing, China). The libraries were normalized and pooled as per the manufacturer’s protocol. Sequencing was performed using the NovaSeq 6000 platform (Illumina, San Diego, CA) with 151 paired-end reads to an average target depth of 100X for germline and tumor samples. Methods used for WES at Hillman Cancer Center were previously published [ 23 ]. Hybridization of 100 ng of FFPE-derived RNA was performed using the Illumina TruSeq exome protocol following the manufacturer’s instructions. Sequencing followed methods previously described [ 23 ]. Computational Analysis. Raw exome sequencing reads were trimmed with Trimmomatic-v0.32 [ 24 ], aligned with bwa-mem-v0.7.8 [ 25 ], and processed with the GATK suite [ 26 ]. Somatic variants were called using the GATK HaplotypeCaller and Mutect2 [ 27 ], retaining those identified in both. Variants with coverage > 10X, a minimum variant allele frequency (VAF) > 0.05, which were predicted to be pathogenic in silico via PolyPhen2 [ 28 ], SIFT [ 29 ], and FATHMM were annotated using SnpEFF-v4.3k [ 30 , 31 ]. Population filters were applied using GnomAD and variants arising in < 1% of the total population were retained [ 32 ]. Priority was assigned to the genes highlighted in Supplemental Table 1 given their known associations with RASopathies and/or gliomas. Copy number variants (CNVs) were identified using both on- and off-target reads with CNVkit v0.8.6 [ 33 ]. Raw sequencing reads were processed with the GenPipes framework [ 34 ]. Reads were qualitatively trimmed with Trimmomatic-v0.32 and aligned to human genome build GRCh37-v75 using STAR-v2.5.0 [ 24 , 35 ]. Fusion transcripts were identified using MetaFusion [ 36 ]. Results were filtered against an in-house database of fusions known to be clinically relevant and consisting of a minimum of three supporting split reads. Internal tandem duplications in FGFR1 were identified using CICERO [ 37 ]. DNA Methylation Profiling. DNA whole-genome bisulfite conversion was performed using the EZ DNA Methylation kit (Zymo Research). DNA from FFPE tissue was subsequently restored by using the Infinium FFPE DNA Restore kit (Illumina). Bisulfite-converted DNA was amplified, fragmented, and purified using the Infinium MethylationEPIC BeadChip Kit (Illumina) according to the manufacturer’s protocol, then hybridized to the BeadChip array (Illumina). The BeadChip array was washed, prepared, stained, and scanned on the Illumina NextSeq 550 (Illumina) per the manufacturer’s protocol. iDAT files were uploaded and classified using version 11b6 and 12.5 of the CNS tumor methylation classifier ( https://www.molecularneuropathology.org/mnp/ ). A calibrated score cutoff of 0.9 was used to determine a successful diagnosis. Copy number variation (CNV) profiles were inferred using the R “conumee” package ( http://bioconductor.org/packages/conumee/ ) as implemented in the classifier package. Statistical analysis. Analysis of correlation between genotype and occurrence of brain tumors in patients with NS was performed by comparing patients’ germline findings in the current study with previously published data using its 95% confidence interval (CI) [ 38 ]. Results Patient Demographics and Clinical Outcomes Twenty-four patients were enrolled in this study, 19 (79%) of which were male. Twenty-two patients were younger than 18 years when diagnosed with CNS cancer. Clinical diagnoses consisted of NS ( n = 19; 79%), cardiofaciocutaneous ( n = 2), Legius, linear nevus sebaceous (LNS), and NS with multiple lentigines syndrome in one patient each ( Table 1 ). All patients had overt phenotypes associated with NNFRAS and were diagnosed before identification of CNS cancers. Five patients without symptoms attributable to CNS tumors were incidentally diagnosed with tumors during work-up for initiation of growth hormone supplementation ( n = 2), seizures ( n = 2, both with infra-tentorial tumors), or developmental delay ( n = 1). After a median follow-up of 7.5 years (range: 0.5–20.2+), one patient with a low-grade glioma died of tumor progression and 3 patients died of causes unrelated to tumor. Ten patients with LGGs received chemotherapy and/or targeted therapy and one with a high-grade glioma underwent local radiation therapy and chemotherapy. None of the patients with histologically confirmed or presumptive DNETs required anticancer therapy ( Table 1 ). Germline Genetic Characteristics Molecular germline analysis via WES of peripheral blood confirmed the diagnoses in 23 (96%) cases (Fig. 1 A) and was used to compare to WES performed from tumor tissue (Fig. 1 B). Germline pathogenic, gain-of-function PTPN11 missense variants occurred in 17 (89%; 95% CI: 0.67–0.99) patients with NS ( Table 1 , Fig. 1 A). The distribution of germline variants in PTPN11 is shown in Fig. 1 C. Two PTPN11 genotypes, NM_002834.5( PTPN11 ):c.182A > G (p.Asp61Gly) and c.417G > T (p.Glu139Asp) were significantly overrepresented in our patients at a two-sided 0.05 significance level ( Supplemental Table 2 ). The second most common NNFRAS driver mutation was RAF1 (n = 2, [Figure 1 D]). Interestingly, 12 (71%) patients with NS had germline FGFR1 genetic abnormalities, including two with FGFR1 and PIK3CA abnormalities and one with FGFR1 and PIK3R1 abnormalities (Fig. 1 E). Genetic and Transcriptomic Characterization of Tumor Specimens To better understand the genetic alterations associated with NS and CNS cancers, we performed WES from FFPE tumor specimens. WES was completed in 15 tumors from 13 (81%) of 16 patients with PTPN11 -associated NS and a confirmed or suspected LGG, including paired multifocal tumors in 2 patients. Fourteen (93%) of 15 tumors harbored a somatic heterozygous FGFR1 hotspot mutation or an internal tandem duplication (ITD) of its tyrosine kinase domain ( n = 1) (Fig. 1 B). While the cerebellar DNET of patient 14 harbored an FGFR1 ITD, his temporal DNET had an NM_023110.3(FGFR1):c.1966A > G (p.Lys656Glu). Patient 15 had an NM_023110.3(FGFR1):c.1638C > A (p.Asn546Lys) in his cerebellar and temporal DNETs, respectively. To identify splicing events and other alterations at the transcript level, RNA sequencing was performed on 12 tumors collected from 10 patients. An FGFR1 ITD was detected in one of patient 14’s tumors. No other transcript fusions were detected. Epigenetic Characterization of Tumor Specimens Whole-genome bisulfite sequencing was performed on 15 tumors, leading to changes in diagnosis for two patients. Patient 3 likely had a diffuse midline glioma, H3 K27M-mutant with CDK4 and MDM2 amplification (calibrated score of 0.87). Despite histological diagnosis of pilocytic astrocytoma, DNA methylation clustered patient 24’s tumor with rosette-forming glioneuronal tumors (calibrated score of 0.99). A summary of DNA methylation results is provided in Supplemental Table 3 . Central Radiological Review and Histological Characteristics Detailed radiological data for all cases are provided in Supplemental Table 4 . Primary tumor site was in the infra-tentorial space ( n = 9), cerebral cortex ( n = 8), diencephalon ( n = 3), optic pathway ( n = 2), and spinal cord ( n = 1). Patient 14 had two separate synchronous tumors of equal size in the temporal lobe and cerebellum at diagnosis (Fig. 2 ) [ 16 ]. Nineteen patients underwent histological tumor confirmation, and five of six asymptomatic cases were diagnosed based on imaging only. Twelve (52%) of 23 evaluable patients, including 9 (47%) with NS, displayed multiple T 2 /fluid-attenuated inversion recovery (FLAIR) hyperintense, non-infiltrative, mostly non-enhancing and cystic, separate lesions deep in brain parenchyma without mass effect (Fig. 2 and Supplemental Table 4 ). Institutional radiological review had already prospectively detected multiple brain lesions in at least 9 cases. Two patients with NS (patients 14 and 15) underwent resection of two separate synchronous and metachronous tumors, respectively, in the temporal lobe and cerebellum ( Supplemental Table 4 ). Among 10 patients without histological confirmation of distant parenchymatous lesions, a multifocal neoplastic process was confirmed based on slow radiological progression over a median of 6.6 years (range, 2.5 + to 20.2+) in 8 patients with NNFRAS, 6 of them with NS ( Supplemental Table 4 ). Two patients had non-progressive multifocal distant tumors suspicious for a neoplastic process since they either shared imaging characteristics with the primary site (FLAIR ring sign [patient 9, Fig. 3 ]) or displayed mass effect with elevated choline and decreased N-acetylaspartate (NAA) on MR spectroscopy (patient 21)[ 39 ]. Multifocal brain lesions affected the posterior fossa (cerebellum and/or brainstem) and thalamus in 9 (100%) and 5 (56%) patients with NS, respectively, which are unusual locations considering their confirmed ( n = 5) or presumptive ( n = 2) diagnosis of dysembryoplastic neuroepithelial tumor (DNET). Five patients experienced intra-tumoral hemorrhage with or without intra-ventricular spread before diagnosis, including both patients with multifocal, histologically confirmed tumors ( Supplemental Table 4 ). Excluding one participant with a diffuse leptomeningeal glioneuronal tumor (DLGNT), which almost uniformly presents with metastatic disease [ 10 ], five patients developed leptomeningeal tumor spread at follow-up confirmed radiologically only, including patient 9 who had a DNET and slowly progressive arachnoid disease (Fig. 3 ). According to institutional histological review, diagnoses were pilocytic/pilomyxoid astrocytoma (WHO grade 1; n = 9 [47%]), DNET (WHO grade 1; n = 6 [32%]), and one each of LGG not otherwise specified (NOS; WHO grade 1), high-grade glioma NOS, schwannoma (WHO grade 1), and DLGNT (Fig. 1 A). DNETs were diagnosed in both patients with histologically confirmed multifocal tumors. Central histological review of these 19 cases was not performed. Discussion Our work provides the first large-scale clinical, radiological, and molecular study evaluating NS-associated brain neoplasms, which were mostly LGGs. There was an overwhelming male predominance observed in NS (79%), similar to previously published case reports (61%; Supplemental Table 5 ) [ 5 , 9 – 20 ], for which this sex bias remains unknown. Brain tumors developed during childhood in most patients with NS and their continued slow growth during adulthood was documented in several cases. Further work is warranted to determine the behavior and repercussions of NS-associated brain tumors in adults. The prevalence of germline PTPN11 variants in NS is approximately 45% [ 40 ]. Herein, we demonstrated an overrepresentation of germline PTPN11 and a genotype-phenotype association between NM_002834.5(PTPN11):c.182A > G (p.Asp61Gly) or c.417G > T (p.Glu139Asp) and the development of brain tumors in patients with NS. These PTPN11 variants, as well as others, are known to induce protein changes and activate mitogen-activated pathway kinase (MAPK) signaling [ 38 ]. Additionally, we discovered a 93% co-occurrence rate of somatic FGFR1 abnormalities and PTPN11 germline variants in patients with NS and LGG. A previously reported in vitro cooperative effect of abnormalities in both genes was shown to cause overexpression of pERK compared to PTPN11 variants alone in murine fibroblasts and was implicated in the tumorigenesis of pilocytic astrocytomas [ 41 ]. Similarly, a recent analysis of FGFR alterations across gliomas, including pediatric gliomas, support the hypothesis of a synergistic effect of PTPN11 and FGFR1 in the genesis of gliomas [ 42 ]. We propose that cooperative interaction between PTPN11 and FGFR1 abnormalities is critical for the tumorigenesis of LGGs in patients with NS, including DNETs. This has potential practical implications for patients with NS, as FGFR1 inhibitors have shown preliminary activity in LGGs harboring FGFR1 variants [ 43 ]. Likewise, other inhibitors of the MAPK pathway (e.g., MEK inhibitors) may represent alternative therapies for patients with NS and LGG. Multiple case reports described the presence of separate parenchymal lesions in patients with NS and NNFRAS [ 9 , 17 , 19 ], but only a few patients underwent histological confirmation [ 16 , 44 , 45 ]. Here, we show that multifocal parenchymal lesions in NS unequivocally represent synchronous or metachronous LGGs based on histological confirmation ( n = 2; 22%), slow growth documented over a median follow-up of 6.6 years ( n = 6; 67%), or typical radiological characteristics ( n = 1, 11%). The only patient with NS without histological confirmation or radiological disease progression harbored a synchronous satellite lesion located in the cerebellum with FLAIR hyperintense ring sign, similar to the primary tumor, which is suggestive of DNETs [ 39 ]. Although this case was previously reported, no details about radiological findings had been provided [ 46 ]. The prevalence of multifocal tumors in 9 (53%) of 17 patients with NS and LGGs, a rate at least twice higher than those for patients with NF1 based on imaging [ 47 ], is striking and warrants confirmation in larger studies. Unlike NF1, only two (11%) of our patients with NS had primary involvement of the optic pathway [ 47 ], which further corroborates the distinct biological, clinical, and radiological tumor characteristics in patients with NS. DNETs and other low-grade glioneuronal tumors accounted for approximately 50% of all CNS tumors in patients with NS and other NNFRAS reported to date [ 5 , 10 , 13 , 14 , 17 – 20 , 45 , 46 , 48 ] ( Supplemental Table 5 ). Likewise, DNETs were overrepresented and commonly displayed multifocal involvement in our patients, an otherwise rare phenomenon [ 49 ]. Therefore, the diagnosis of NS or other NNFRAS should be investigated in patients suspected to harbor multifocal LGGs. Based on a previous report [ 44 ], it is possible that individuals with NS and other NNFRAS could have histologically distinct multifocal LGGs. We also report a few unique cases, including the first association of Legius syndrome with a CNS cancer and a second case of a presumed brain tumor in a child with cardiofaciocutaneous syndrome. Unfortunately, no tumor tissue was available in either patient for molecular analysis. Although most patients did not require anticancer therapy beyond surgery, 7 (41%) of 17 patients with NS and a confirmed or presumptive LGG required standard chemotherapy and/or targeted agents, 5 of whom %) received at least 2 different regimens. Overall, NS-associated CNS tumors are mostly non-life-threatening LGGs with indolent growth, but may present with complications, including disease progression, leptomeningeal spread, significant morbidity, and even death despite aggressive therapy. One limitation of this study is its mostly retrospective design. Although 7 patients had been included in other reports [ 9 – 11 , 16 , 45 , 46 ], we generated extensive new clinical, radiological, and molecular data about them. Based on the patients’ overt presentation of NS and NNFRAS, our findings may not be applicable to those with subtle features who are diagnosed based on molecular screening after the diagnosis of CNS tumors [ 17 ]. In conclusion, patients with NS and germline PTPN11 variants account for nearly all individuals with NNFRAS and brain tumors in this study. Although approximately half of these patients harbored multifocal LGGs, their prognosis was good. However, anticancer therapy is required in a substantial minority of patients, particularly those with DNETs. Our finding that 93% of patients with NS and LGG harbor FGFR1 mutations provides an exciting new therapeutic opportunity for these patients. Further investigation with CNS imaging is recommended for patients with NNFRAS presenting with neurologic signs and/or symptoms. Screening of asymptomatic patients with NM_002834.5(PTPN11):c.182A > G (p.Asp61Gly) or c.417G > T (p.Glu139Asp) variants for brain tumors may also be considered. Declarations Conflict of Interest: The authors declare no conflict of interest relevant to this work. Funding: This work was supported in part by funds provided by the Wheeler family, the Haley Weiss Memorial Fund, and by a P30CA047904 award to the UPMC Hillman Cancer Center Core Laboratory Author Contribution Access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis: G.K. and A.B. Concept and design: G.K. and A.B. Recruitment of study participants : L.M.H., A.E.B., K.W.G., A.W.W., J.R.H., A.A.S, and A.B. Central radiologic review : A.B. Generation of molecular data : G.K. and A.B. Analysis of molecular data : S.R., R.S., J.M.S., U.T., and C.E.H. Statistical analysis : H.W. Writing of the manuscript at draft and any revision stages, and approval of its final version : G.K., S.R., S.E.G, L.M.H., R.S., A.E.B., K.W.G., A.W.W., J.R.H., A.A.S., H.W., J.M.S., U.T., C.E.H., and A.B. Acknowledgement We thank Maureen Lyons for expertise in performing molecular studies, Dr. Marina N. Nikifirova and Dr. Abigail I. Wald for assisting with DNA methylation profiling, and Beth Stronach and Amanda Brown (Noonan Syndrome Foundation) for helping several patient families volunteer for study participation. We are indebted to the patients and their families for their willingness to participate in this study. Data Availability Deidentified whole exome sequencing, RNA sequencing, and DNA methylation sequencing data will be deposited to GEO or EGA and made freely available. References Fiala EM, Jayakumaran G, Mauguen A, Kennedy JA, Bouvier N, Kemel Y, Fleischut MH, Maio A, Salo-Mullen EE, Sheehan M, Arnold AG, Latham A, Carlo MI, Cadoo K, Murkherjee S, Slotkin EK, Trippett T, Glade Bender J, Meyers PA, Wexler L, Dela Cruz FS, Cheung NK, Basu E, Kentsis A, Ortiz M, Francis JH, Dunkel IJ, Khakoo Y, Gilheeney S, Farouk Sait S, Forlenza CJ, Sulis M, Karajannis M, Modak S, Gerstle JT, Heaton TE, Roberts S, Yang C, Jairam S, Vijai J, Topka S, Friedman DN, Stadler ZK, Robson M, Berger MF, Schultz N, Ladanyi M, O'Reilly RJ, Abramson DH, Ceyhan-Birsoy O, Zhang L, Mandelker D, Shukla NN, Kung AL, Offit K, Zehir A, Walsh MF (2021) Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nat Cancer 2: 357-365 doi:10.1038/s43018-021-00172-1 Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, Barahona P, Wilkie EE, Sullivan P, Bowen-James R, Syed M, Martincorena I, Abascal F, Sherstyuk A, Bolanos NA, Baber J, Priestley P, Dolman MEM, Fleuren EDG, Gauthier ME, Mould EVA, Gayevskiy V, Gifford AJ, Grebert-Wade D, Strong PA, Manouvrier E, Warby M, Thomas DM, Kirk J, Tucker K, O'Brien T, Alvaro F, McCowage GB, Dalla-Pozza L, Gottardo NG, Tapp H, Wood P, Khaw SL, Hansford JR, Moore AS, Norris MD, Trahair TN, Lock RB, Tyrrell V, Haber M, Marshall GM, Ziegler DS, Ekert PG, Cowley MJ (2020) Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med 26: 1742-1753 doi:10.1038/s41591-020-1072-4 Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR (2015) Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 373: 2336-2346 doi:10.1056/NEJMoa1508054 Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS (2011) Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 157C: 83-89 doi:10.1002/ajmg.c.30300 Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlhase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schluter G, Gencik M, Uberlacker B, Lissewski C, Schanze I, Greene MH, Spix C, Zenker M (2015) Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer 112: 1392-1397 doi:10.1038/bjc.2015.75 Lin AL, Gutmann DH (2013) Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol 10: 616-624 doi:10.1038/nrclinonc.2013.144 Dunnett-Kane V, Burkitt-Wright E, Blackhall FH, Malliri A, Evans DG, Lindsay CR (2020) Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. Ann Oncol 31: 873-883 doi:10.1016/j.annonc.2020.03.291 Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013) Noonan syndrome. Lancet 381: 333-342 doi:10.1016/S0140-6736(12)61023-X Chiang MC, McDowell MM, Weaver K, Broniscer A, Greene S (2019) Is Schimmelpenning Syndrome Associated with Intracranial Tumors? A Case Report. Pediatr Neurosurg 54: 201-206 doi:10.1159/000497149 Dodgshun AJ, SantaCruz N, Hwang J, Ramkissoon SH, Malkin H, Bergthold G, Manley P, Chi S, MacGregor D, Goumnerova L, Sullivan M, Ligon K, Beroukhim R, Herrington B, Kieran MW, Hansford JR, Bandopadhayay P (2016) Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol 128: 293-302 doi:10.1007/s11060-016-2109-x El-Ayadi M, Ansari M, Kuhnol CD, Bendel A, Sturm D, Pietsch T, Kramm CM, von Bueren AO (2019) Occurrence of high-grade glioma in Noonan syndrome: Report of two cases. Pediatr Blood Cancer 66: e27625 doi:10.1002/pbc.27625 Fryssira H, Leventopoulos G, Psoni S, Kitsiou-Tzeli S, Stavrianeas N, Kanavakis E (2008) Tumor development in three patients with Noonan syndrome. Eur J Pediatr 167: 1025-1031 doi:10.1007/s00431-007-0636-3 Karafin M, Jallo GI, Ayars M, Eberhart CG, Rodriguez FJ (2011) Rosette forming glioneuronal tumor in association with Noonan syndrome: pathobiological implications. Clin Neuropathol 30: 297-300 doi:10.5414/np300374 Lin FY, Bergstrom K, Person R, Bavle A, Ballester LY, Scollon S, Raesz-Martinez R, Jea A, Birchansky S, Wheeler DA, Berg SL, Chintagumpala MM, Adesina AM, Eng C, Roy A, Plon SE, Parsons DW (2016) Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle. Cold Spring Harb Mol Case Stud 2: a001057 doi:10.1101/mcs.a001057 Martinelli S, Carta C, Flex E, Binni F, Cordisco EL, Moretti S, Puxeddu E, Tonacchera M, Pinchera A, McDowell HP, Dominici C, Rosolen A, Di Rocco C, Riccardi R, Celli P, Picardo M, Genuardi M, Grammatico P, Sorcini M, Tartaglia M (2006) Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 166: 124-129 doi:10.1016/j.cancergencyto.2005.10.003 McWilliams GD, SantaCruz K, Hart B, Clericuzio C (2016) Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy. Am J Med Genet A 170A: 195-201 doi:10.1002/ajmg.a.37379 Shatara M, Schieffer KM, Melas M, Varga EA, Thomas D, Bucknor BA, Costello HM, Wheeler G, Kelly BJ, Miller KE, Rodriguez DP, Mathew MT, Lee K, Crotty E, Leary S, Paulson VA, Cole B, Abdelbaki MS, Finlay JL, Lazow MA, Salloum R, Fouladi M, Boue DR, Mardis ER, Cottrell CE (2024) Molecular characterization of gliomas and glioneuronal tumors amid Noonan syndrome: cancer predisposition examined. Front Oncol 14: 1453309 doi:10.3389/fonc.2024.1453309 Sherman CB, Ali-Nazir A, Gonzales-Gomez I, Finlay JL, Dhall G (2009) Primary mixed glioneuronal tumor of the central nervous system in a patient with noonan syndrome: a case report and review of the literature. J Pediatr Hematol Oncol 31: 61-64 doi:10.1097/MPH.0b013e31818ab2cf Siegfried A, Cances C, Denuelle M, Loukh N, Tauber M, Cave H, Delisle MB (2017) Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature. Am J Med Genet A 173: 1061-1065 doi:10.1002/ajmg.a.38108 Sievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wefers AK, Reinhardt A, Coras R, Ruf VC, Schmid S, de Stricker K, Boldt HB, Kristensen BW, Petersen JK, Ulhoi BP, Gardberg M, Aronica E, Hasselblatt M, Bruck W, Bielle F, Mokhtari K, Lhermitte B, Wick W, Herold-Mende C, Hanggi D, Brandner S, Giangaspero F, Capper D, Rushing E, Wesseling P, Pfister SM, Figarella-Branger D, von Deimling A, Sahm F, Jones DTW (2019) Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathol 138: 497-504 doi:10.1007/s00401-019-02038-4 Valera ET, McConechy MK, Gayden T, Rivera B, Jones DTW, Wittmann A, Han H, Bareke E, Nikbakht H, Mikael L, Queiroz RG, Suazo VK, Phi JH, Kim SK, Park SH, Fukaya R, Yum MS, Ko TS, de Oliveira RS, Machado HR, Brassesco MS, do Santos AC, Simao GN, Ramalho LNZ, Neder L, Scrideli CA, Tone LG, Majewski J, Jabado N (2018) Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. Acta Neuropathol 136: 657-660 doi:10.1007/s00401-018-1898-8 Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Gilheeney S, Rosenblum M, Bale T, Tsang DS, Laperriere N, Kulkarni A, Ibrahim GM, Drake J, Dirks P, Taylor MD, Rutka JT, Laughlin S, Shroff M, Shago M, Hazrati LN, D'Arcy C, Ramaswamy V, Bartels U, Huang A, Bouffet E, Karajannis MA, Santi M, Ellison DW, Tabori U, Hawkins C (2020) Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 37: 569-583 e565 doi:10.1016/j.ccell.2020.03.011 Mehrad M, LaFramboise WA, Lyons MA, Trejo Bittar HE, Yousem SA (2018) Whole-exome sequencing identifies unique mutations and copy number losses in calcifying fibrous tumor of the pleura: report of 3 cases and review of the literature. Hum Pathol 78: 36-43 doi:10.1016/j.humpath.2018.04.005 Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30: 2114-2120 doi:10.1093/bioinformatics/btu170 Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595 doi:10.1093/bioinformatics/btp698 Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S, DePristo MA (2013) From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics 43: 11 10 11-11 10 33 doi:10.1002/0471250953.bi1110s43 Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31: 213-219 doi:10.1038/nbt.2514 Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249 doi:10.1038/nmeth0410-248 Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC (2016) SIFT missense predictions for genomes. Nat Protoc 11: 1-9 doi:10.1038/nprot.2015.123 Shihab HA, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR (2014) Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. Hum Genomics 8: 11 doi:10.1186/1479-7364-8-11 Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6: 80-92 doi:10.4161/fly.19695 Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Genome Aggregation Database C, Neale BM, Daly MJ, MacArthur DG (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581: 434-443 doi:10.1038/s41586-020-2308-7 Talevich E, Shain AH, Botton T, Bastian BC (2016) CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 12: e1004873 doi:10.1371/journal.pcbi.1004873 Bourgey M, Dali R, Eveleigh R, Chen KC, Letourneau L, Fillon J, Michaud M, Caron M, Sandoval J, Lefebvre F, Leveque G, Mercier E, Bujold D, Marquis P, Van PT, Anderson de Lima Morais D, Tremblay J, Shao X, Henrion E, Gonzalez E, Quirion PO, Caron B, Bourque G (2019) GenPipes: an open-source framework for distributed and scalable genomic analyses. Gigascience 8 doi:10.1093/gigascience/giz037 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21 doi:10.1093/bioinformatics/bts635 Apostolides M, Li M, Arnoldo A, Ku M, Husic M, Ramani AK, Brudno M, Turinsky A, Hawkins C, Siddaway R (2023) Clinical Implementation of MetaFusion for Accurate Cancer-Driving Fusion Detection from RNA Sequencing. J Mol Diagn 25: 921-931 doi:10.1016/j.jmoldx.2023.09.002 Tian L, Li Y, Edmonson MN, Zhou X, Newman S, McLeod C, Thrasher A, Liu Y, Tang B, Rusch MC, Easton J, Ma J, Davis E, Trull A, Michael JR, Szlachta K, Mullighan C, Baker SJ, Downing JR, Ellison DW, Zhang J (2020) CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. Genome Biol 21: 126 doi:10.1186/s13059-020-02043-x Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt I, Palleschi A, Petrucci TC, Sorcini M, Schoch C, Foa R, Emanuel PD, Gelb BD (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78: 279-290 doi:10.1086/499925 Parmar HA, Hawkins C, Ozelame R, Chuang S, Rutka J, Blaser S (2007) Fluid-attenuated inversion recovery ring sign as a marker of dysembryoplastic neuroepithelial tumors. J Comput Assist Tomogr 31: 348-353 doi:10.1097/01.rct.0000243453.33610.9d Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70: 1555-1563 doi:10.1086/340847 Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stutz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM, International Cancer Genome Consortium PedBrain Tumor P (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45: 927-932 doi:10.1038/ng.2682 Apfelbaum AA, Morin E, Sturm D, Ayoub G, DiGiacomo J, Bahadur S, Chandarana B, Power PC, Cusick MM, Novikov D, Prabhakar P, Jones RE, Vogelzang J, Bossi CC, Malinowski S, Woodward LM, Jones TA, Jeang J, Lamson SW, Collins J, Cai KY, Jones JS, Oh S, Jeon H, Wang J, Cameron A, Rechter P, De Leon A, Murugesan K, Montesion M, Albacker LA, Ramkissoon SH, van Tilburg CM, Hardin EC, Sievers P, Sahm F, Yeo KK, Rosenberg T, Chi SN, Wright KD, Hebert S, Peck S, Picca A, Larouche V, Renzi S, Buhrlage SJ, Bale TA, Smith AA, Touat M, Jabado N, Fischer ES, Eck MJ, Baird L, Witt O, Kleinman CL, Nguyen QD, Sheer D, Alexandrescu S, Jones DTW, Ligon KL, Bandopadhayay P (2025) A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. Nat Commun 16: 7018 doi:10.1038/s41467-025-61820-z Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y, Investigators R (2023) Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 24: 925-935 doi:10.1016/S1470-2045(23)00275-9 Lodi M, Boccuto L, Carai A, Cacchione A, Miele E, Colafati GS, Diomedi Camassei F, De Palma L, De Benedictis A, Ferretti E, Catanzaro G, Po A, De Luca A, Rinelli M, Lepri FR, Agolini E, Tartaglia M, Locatelli F, Mastronuzzi A (2020) Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature. Diagnostics (Basel) 10 doi:10.3390/diagnostics10080582 Tuohy K, Lane J, Abendroth C, Iantosca M (2022) A Constellation of Atypical Findings in a Nine-Year-Old Child With Dysembryoplastic Neuroepithelial Tumors: A Case Report and Review of the Literature. Cureus 14: e27707 doi:10.7759/cureus.27707 Bangalore Krishna K, Pagan P, Escobar O, Popovic J (2017) Occurrence of Cranial Neoplasms in Pediatric Patients with Noonan Syndrome Receiving Growth Hormone: Is Screening with Brain MRI prior to Initiation of Growth Hormone Indicated? Horm Res Paediatr 88: 423-426 doi:10.1159/000479107 Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P, Reseau NFF (2003) Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126: 152-160 doi:10.1093/brain/awg016 Sanford RA, Bowman R, Tomita T, De Leon G, Palka P (1999) A 16-year-old male with Noonan's syndrome develops progressive scoliosis and deteriorating gait. Pediatr Neurosurg 30: 47-52 doi:10.1159/000028761 Lellouch-Tubiana A, Bourgeois M, Vekemans M, Robain O (1995) Dysembryoplastic neuroepithelial tumors in two children with neurofibromatosis type 1. Acta Neuropathol 90: 319-322 doi:10.1007/BF00296517 Table Table 1 is available in the Supplementary Files section. Additional Declarations No competing interests reported. Supplementary Files Table1.docx SupplTable1ListGenes.xlsx SupplTable2GenotypeDistribution.xlsx SupplTable3DNAMethylation.xlsx SupplTable4Radiology.xlsx SupplTable5PastExperience.xlsx SupplementalTableLegends.docx Cite Share Download PDF Status: Published Journal Publication published 05 Mar, 2026 Read the published version in Journal of Neuro-Oncology → Version 1 posted Editorial decision: Revision requested 06 Feb, 2026 Reviews received at journal 05 Feb, 2026 Reviews received at journal 05 Feb, 2026 Reviews received at journal 05 Feb, 2026 Reviews received at journal 28 Jan, 2026 Reviewers agreed at journal 28 Jan, 2026 Reviewers agreed at journal 27 Jan, 2026 Reviewers agreed at journal 26 Jan, 2026 Reviews received at journal 25 Jan, 2026 Reviewers agreed at journal 22 Jan, 2026 Reviewers agreed at journal 22 Jan, 2026 Reviewers invited by journal 22 Jan, 2026 Editor assigned by journal 22 Jan, 2026 Submission checks completed at journal 22 Jan, 2026 First submitted to journal 21 Jan, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8662616","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":580743175,"identity":"df271825-3e1c-46b5-ba89-82dabcff690b","order_by":0,"name":"Gary Kohanbash","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAUlEQVRIie3RsUvDQBTH8XdEMiV0fVAw/8KVQik0u//GBeGyJFmEzplusmQNFPRfqJtjQsApZn5CB6fMcTODaNNOCjl1E7zv+ODD7+AATKY/WwECwAFgqX8OOFzsnxM5/zWpgvQ74l08tgi1n0y2m/Klv7fCbLspoFtXo2RWhwsEkle4by6nbm3H+b4RLG80JJU2Qnd4D0V8ypQT7zDilqs0JGtP5Jaied8rDPlA3jTEw2GFqmBH0QJdxcWRMA3h2FpLUcvgjhK5cpWY5ZSI8roJx1cyyah78IMbiqunXr17kzwun1/Xq/GVAs5QfL45h3/S5KVgdV9ujg6YTCbTP+wDyb5c23ggXJYAAAAASUVORK5CYII=","orcid":"","institution":"University of Pittsburgh","correspondingAuthor":true,"prefix":"","firstName":"Gary","middleName":"","lastName":"Kohanbash","suffix":""},{"id":580743176,"identity":"2df66ed9-1aca-474e-aa33-b174f1db0702","order_by":1,"name":"Scott Ryall","email":"","orcid":"","institution":"Hospital for Sick Children","correspondingAuthor":false,"prefix":"","firstName":"Scott","middleName":"","lastName":"Ryall","suffix":""},{"id":580743177,"identity":"89a8a303-b5c8-49c9-affe-41b2bb1b57c6","order_by":2,"name":"Sam E. Gary","email":"","orcid":"","institution":"University of Pittsburgh","correspondingAuthor":false,"prefix":"","firstName":"Sam","middleName":"E.","lastName":"Gary","suffix":""},{"id":580743178,"identity":"274259c9-1b75-4ff5-8cb6-4bbc8c2780e6","order_by":3,"name":"Lindsey M. Hoffman","email":"","orcid":"","institution":"Children's Hospital Colorado","correspondingAuthor":false,"prefix":"","firstName":"Lindsey","middleName":"M.","lastName":"Hoffman","suffix":""},{"id":580743179,"identity":"529d841e-48e7-4950-8d37-1122858d8a5e","order_by":4,"name":"Robert Siddaway","email":"","orcid":"","institution":"Hospital for Sick Children","correspondingAuthor":false,"prefix":"","firstName":"Robert","middleName":"","lastName":"Siddaway","suffix":""},{"id":580743180,"identity":"ecb8be39-36ca-4336-835e-aa5c8c8e4237","order_by":5,"name":"Anne E. Bendel","email":"","orcid":"","institution":"Children's Minnesota","correspondingAuthor":false,"prefix":"","firstName":"Anne","middleName":"E.","lastName":"Bendel","suffix":""},{"id":580743181,"identity":"4b0465d6-de42-4417-8c52-18137ae3f164","order_by":6,"name":"Karen W. Gripp","email":"","orcid":"","institution":"Alfred I. duPont Hospital for Children","correspondingAuthor":false,"prefix":"","firstName":"Karen","middleName":"W.","lastName":"Gripp","suffix":""},{"id":580743182,"identity":"27a41905-0673-4741-ba7f-d530ce4fd0b9","order_by":7,"name":"Andrew W. Walter","email":"","orcid":"","institution":"Alfred I. duPont Hospital for Children","correspondingAuthor":false,"prefix":"","firstName":"Andrew","middleName":"W.","lastName":"Walter","suffix":""},{"id":580743183,"identity":"09bbc24d-bb52-4457-85de-237089c54104","order_by":8,"name":"Jordan R. Hansford","email":"","orcid":"","institution":"Royal Children's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Jordan","middleName":"R.","lastName":"Hansford","suffix":""},{"id":580743184,"identity":"867835c8-3a9c-43cc-92d9-213b6ac4d13b","order_by":9,"name":"Amy A. Smith","email":"","orcid":"","institution":"Arnold Palmer Hospital for Children","correspondingAuthor":false,"prefix":"","firstName":"Amy","middleName":"A.","lastName":"Smith","suffix":""},{"id":580743185,"identity":"e130f71c-c4ff-465b-b3aa-93823f02e182","order_by":10,"name":"Hong Wang","email":"","orcid":"","institution":"University of Pittsburgh","correspondingAuthor":false,"prefix":"","firstName":"Hong","middleName":"","lastName":"Wang","suffix":""},{"id":580743186,"identity":"646c2c35-eb5a-42d4-8980-edcb606a8db1","order_by":11,"name":"John M. Skaugen","email":"","orcid":"","institution":"University of Pittsburgh","correspondingAuthor":false,"prefix":"","firstName":"John","middleName":"M.","lastName":"Skaugen","suffix":""},{"id":580743187,"identity":"67fa4fa6-cf83-42ab-92b6-52b8bc1f49de","order_by":12,"name":"Uri Tabori","email":"","orcid":"","institution":"Hospital for Sick Children","correspondingAuthor":false,"prefix":"","firstName":"Uri","middleName":"","lastName":"Tabori","suffix":""},{"id":580743188,"identity":"a2d6c781-9a08-4b00-b99f-5254b0935f45","order_by":13,"name":"Cynthia E. Hawkins","email":"","orcid":"","institution":"University of Toronto","correspondingAuthor":false,"prefix":"","firstName":"Cynthia","middleName":"E.","lastName":"Hawkins","suffix":""},{"id":580743189,"identity":"0abb1878-a7ff-4b1d-a5dc-8e4a502fa37e","order_by":14,"name":"Alberto Broniscer","email":"","orcid":"","institution":"Children's Hospital of Pittsburgh","correspondingAuthor":false,"prefix":"","firstName":"Alberto","middleName":"","lastName":"Broniscer","suffix":""}],"badges":[],"createdAt":"2026-01-21 17:54:53","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8662616/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8662616/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s11060-026-05478-7","type":"published","date":"2026-03-05T15:58:55+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":101297858,"identity":"b68b3eb2-5c78-48a5-be0a-028fac0fe085","added_by":"auto","created_at":"2026-01-28 09:29:07","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":416900,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMolecular characterization of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ePTPN11\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e-Related Noonan Syndrome Predisposed Multifocal Low-Grade Gliomas.\u003c/strong\u003e (A) Oncoprint for all 24 patient. (B) Oncoprint for patients whose tumors underwent whole-exome sequencing. (C) Distribution of \u003cem\u003ePTPN11\u003c/em\u003e germline variants. (D) Distribution of RASopathy driver mutations. (E) Secondary tumor molecular abnormalities.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/9c87555fdc10f5aa7e00e11e.png"},{"id":101273498,"identity":"4cfdc180-af1e-4230-927c-dd7863cde32e","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":283304,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eRadiologic characteristics of a multifocal DNET. \u003c/strong\u003e(A) Axial T\u003csub\u003e2\u003c/sub\u003e-weighted MRI in patient 14 showed hyperintense, septated lesion in right temporal lobe (white arrow), which was confirmed to be a dysembryoplastic neuroepithelial tumor (WHO grade 1). The deeper aspect of the tumor was shown to have a hemorrhagic area by gradient echo sequence. (B) Axial T\u003csub\u003e2\u003c/sub\u003e-weighted MRI in patient 14 obtained on the same day showed a separate lesion in the right cerebellum (white arrow) with hyperintense rim and an eccentric isointense central area (white arrowhead) compatible with hemorrhage. This lesion was also confirmed to be a dysembryoplastic neuroepithelial tumor (WHO grade 1). (C) Gradient echo sequence confirmed cerebellar tumor hemorrhage (white arrowhead).\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/21d6fb31cb530bcc698bfe62.png"},{"id":101273496,"identity":"ffe64c5d-12a1-4fb4-aff6-b90381a1c735","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":398279,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMRI of patient 9 with multifocal DNET and leptomeningeal dissemination.\u003c/strong\u003e(A) Sagittal FLAIR post contrast image showed enlarging enhancing nodules in the dorsal brainstem (lower white arrowhead) and in the inter-hemispheric fissure (upper white arrowhead) compatible with progressive leptomeningeal disease 7 years after diagnosis of multifocal dysembryoplastic neuroepithelial tumor (WHO grade 1) with primary tumor in the right temporal lobe. (B) Sagittal FLAIR post-contrast image obtained on the same day showed residual hyperintense right temporal lobe tumor (red arrowhead) and surgical cavity (white star). Additional enhancing leptomeningeal punctate lesion was also seen in the right frontal lobe (white arrowhead). (C) Sagittal FLAIR post contrast image obtained on the same day showed a second distinct lesion in the right cerebellum with a typical ring sign (lower white arrowhead) and intra-ventricular punctate enhancing lesion compatible with leptomeningeal spread (upper white arrowhead).\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/0662183d87ea7b79d95c4e5d.png"},{"id":104251650,"identity":"01254aa6-092d-4463-9c2f-77e5d02e8508","added_by":"auto","created_at":"2026-03-09 16:14:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2052551,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/3898645b-aa13-4ffd-805a-75eea483c7e3.pdf"},{"id":101273495,"identity":"7a0842aa-beb8-4e27-83d2-d01af41ad2cb","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":32199,"visible":true,"origin":"","legend":"","description":"","filename":"Table1.docx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/daa17bdca4d7c4566259b8cd.docx"},{"id":101273501,"identity":"08a1d102-2cee-4db0-85ee-a5410c2a6a72","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":10585,"visible":true,"origin":"","legend":"","description":"","filename":"SupplTable1ListGenes.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/f7c24d5e6718aba524700283.xlsx"},{"id":101273500,"identity":"835d553f-814e-4dc8-8f4c-b9208a09524b","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":9623,"visible":true,"origin":"","legend":"","description":"","filename":"SupplTable2GenotypeDistribution.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/7bc67a52100ce706c68ec9ed.xlsx"},{"id":101273499,"identity":"bbd69c59-c77d-4aa9-a80f-0f36953dce9f","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"xlsx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":10586,"visible":true,"origin":"","legend":"","description":"","filename":"SupplTable3DNAMethylation.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/0e88bd5588decb085dd36f35.xlsx"},{"id":101297576,"identity":"e1702f60-8fe7-4cb6-8572-e6948bf72004","added_by":"auto","created_at":"2026-01-28 09:28:03","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":12001,"visible":true,"origin":"","legend":"","description":"","filename":"SupplTable4Radiology.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/e481a97ff3fcdfabc8f00632.xlsx"},{"id":101273502,"identity":"2fd8a791-18ef-48cc-9f41-ca98414b47a3","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"xlsx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":14699,"visible":true,"origin":"","legend":"","description":"","filename":"SupplTable5PastExperience.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/eb4a2f29dc9a1721647a257a.xlsx"},{"id":101273504,"identity":"f0097f30-4585-4305-804e-3962a152b277","added_by":"auto","created_at":"2026-01-28 03:06:04","extension":"docx","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":26286,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalTableLegends.docx","url":"https://assets-eu.researchsquare.com/files/rs-8662616/v1/65186a18857dbeef484c2558.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants","fulltext":[{"header":"Key points","content":"\u003cul\u003e\n \u003cli\u003eMultifocal low-grade glial and glioneuronal tumors are common in patients with Noonan syndrome, especially in males.\u003c/li\u003e\n \u003cli\u003eConcurrent \u003cem\u003ePTPN11\u003c/em\u003e and \u003cem\u003eFGFR1\u003c/em\u003e variants exist in nearly all patients with Noonan syndrome and LGG.\u003c/li\u003e\n \u003cli\u003eTargeting FGFR1may provide novel treatment options for patients with Noonan syndrome and LGG.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eTranslational Relevance:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNoonan syndrome (NS) has been recognized as a genetic predisposition to CNS tumors. However, no long-term clinical, radiological, or molecular patient data have previously been reported in a large patient cohort. Herein, we show that individuals with NS and germline \u003cem\u003ePTPN11\u003c/em\u003e variants, particularly those with NM_002834.5(PTPN11):c.182A\u0026gt;G (p.Asp61Gly) and NM_002834.5(PTPN11):c.417G\u0026gt;C (p.Glu139Asp), are predisposed to develop low-grade gliomas (LGGs; pure and mixed glioneuronal), which may have multifocal distant brain involvement in up to 50% of patients. An overwhelming male predominance was confirmed, for which the biological underpinnings remain unknown. Somatic \u003cem\u003eFGFR1\u003c/em\u003e variants were detected in 93% of LGGs in individuals with \u003cem\u003ePTPN11\u003c/em\u003e-related NS. Therefore, concurrent variants in both genes seem to be required to drive gliomagenesis. Most LGGs experienced indolent behavior, even in the presence of residual disease, and the affected patients experienced long-term survival. However, aggressive monitoring and treatment may be necessary in a subset of patients.\u0026nbsp;\u003c/p\u003e"},{"header":"Introduction","content":"\u003cp\u003eCancer predisposition syndromes are present in 8% to 21% of pediatric patients with central nervous system (CNS) cancers [\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Inhibition of RAS signaling through germline abnormalities in \u003cem\u003eNF1\u003c/em\u003e, as well as germline abnormalities in non-\u003cem\u003eNF1\u003c/em\u003e RASopathies (NNFRAS), is associated with non-CNS cancers [\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. NNFRAS comprise a large and heterogenous group of disorders, the most common of which is Noonan syndrome (NS), with an incidence of up to 1:1,000 live births [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Multiple case reports and one case series (n\u0026thinsp;=\u0026thinsp;5 patients) have described the association of NNFRAS [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan additionalcitationids=\"CR10 CR11 CR12 CR13 CR14 CR15 CR16 CR17 CR18 CR19\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e], particularly NS, with low-grade glioma (LGG). However, no large-scale data exist that that characterize clinical, radiological, and molecular features driving tumorigenesis and patient outcomes [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBased on the prevalence of NS, the overlap between germline abnormalities found in NNFRAS and somatic changes found in pediatric CNS cancers, and our institutional experience [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e], we conducted this multi-institutional study consisting of the largest reported patient population to evaluate clinical, radiological, and molecular characteristics that underlie NS and development of LGG. Leveraging this large cohort, we unveil novel, consistent associations between NS and LGG, including multifocal involvement and co-occurrence of germline \u003cem\u003ePTPN11\u003c/em\u003e and somatic \u003cem\u003eFGFR1\u003c/em\u003e abnormalities, indicating potentially new FGFR1-targeted treatment options.\u003c/p\u003e"},{"header":"Material and Methods","content":"\u003cp\u003e\u003cem\u003eData and sample collection.\u003c/em\u003e Once Institutional Review Board approval (University of Pittsburgh #19060202) was obtained at six participating institutions in the US and Australia, patients with NNFRAS and CNS cancers were recruited to this study. CNS cancers were either histologically confirmed or suspected based on imaging characteristics. Except for three deceased patients, informed consent to study participation was obtained from adult patients, parents, or legal guardians. Assent and re-consent at age of majority were obtained according to institutional standards. Clinical information consisting of demographics, characteristics of NNFRAS, diagnosis and therapy of CNS cancers, and survival were obtained from all research participants. An experienced pediatric neuro-oncologist (A.B.) performed central radiological review of pertinent scans, including MRI and CT at diagnosis and at most recent available follow-up.\u003c/p\u003e \u003cp\u003e \u003cem\u003eWhole Exome (WES) and RNA Sequencing.\u003c/em\u003e Germline DNA was extracted from either blood or saliva, and DNA and RNA were extracted from tumor samples, mostly derived from formalin-fixed, paraffin-embedded (FFPE) tissue, following standard methods. WES was performed at Novogene Corporation Inc. (Sacramento, CA) or at UPMC Hillman Cancer Center Core Laboratory. For WES done at Novogene, extracted DNA was quantified using Qubit TM dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA). DNA libraries were prepared using Agilent SureSelect system (Agilent Technologies, Santa Clara, CA) to capture DNA coding sequences. 400 ng of genomic DNA was processed through fragmentation, enzymatic end-repair and A-tailing, adapter ligation, RNA probe hybridization, and polymerase chain reaction (PCR) amplification. The quality of libraries was analyzed with the DNA NGS 3K Assay Kit and LabChip GX Chip (PerkinElmer, Waltham, MA). Libraries with an average size of 400 bp (range: 300\u0026ndash;600 bp) were quantified by qPCR using the VAHTS Library Quantification Kit for Illumina (Vazyme, Nanjing, China). The libraries were normalized and pooled as per the manufacturer\u0026rsquo;s protocol. Sequencing was performed using the NovaSeq 6000 platform (Illumina, San Diego, CA) with 151 paired-end reads to an average target depth of 100X for germline and tumor samples. Methods used for WES at Hillman Cancer Center were previously published [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Hybridization of 100 ng of FFPE-derived RNA was performed using the Illumina TruSeq exome protocol following the manufacturer\u0026rsquo;s instructions. Sequencing followed methods previously described [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cem\u003eComputational Analysis.\u003c/em\u003e Raw exome sequencing reads were trimmed with Trimmomatic-v0.32 [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e], aligned with bwa-mem-v0.7.8 [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e], and processed with the GATK suite [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Somatic variants were called using the GATK HaplotypeCaller and Mutect2 [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e], retaining those identified in both. Variants with coverage\u0026thinsp;\u0026gt;\u0026thinsp;10X, a minimum variant allele frequency (VAF)\u0026thinsp;\u0026gt;\u0026thinsp;0.05, which were predicted to be pathogenic in silico via PolyPhen2 [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e], SIFT [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e], and FATHMM were annotated using SnpEFF-v4.3k [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Population filters were applied using GnomAD and variants arising in \u0026lt;\u0026thinsp;1% of the total population were retained [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Priority was assigned to the genes highlighted in \u003cb\u003eSupplemental Table\u0026nbsp;1\u003c/b\u003e given their known associations with RASopathies and/or gliomas. Copy number variants (CNVs) were identified using both on- and off-target reads with CNVkit v0.8.6 [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. Raw sequencing reads were processed with the GenPipes framework [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. Reads were qualitatively trimmed with Trimmomatic-v0.32 and aligned to human genome build GRCh37-v75 using STAR-v2.5.0 [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. Fusion transcripts were identified using MetaFusion [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Results were filtered against an in-house database of fusions known to be clinically relevant and consisting of a minimum of three supporting split reads. Internal tandem duplications in FGFR1 were identified using CICERO [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cem\u003eDNA Methylation Profiling.\u003c/em\u003e DNA whole-genome bisulfite conversion was performed using the EZ DNA Methylation kit (Zymo Research). DNA from FFPE tissue was subsequently restored by using the Infinium FFPE DNA Restore kit (Illumina). Bisulfite-converted DNA was amplified, fragmented, and purified using the Infinium MethylationEPIC BeadChip Kit (Illumina) according to the manufacturer\u0026rsquo;s protocol, then hybridized to the BeadChip array (Illumina). The BeadChip array was washed, prepared, stained, and scanned on the Illumina NextSeq 550 (Illumina) per the manufacturer\u0026rsquo;s protocol. iDAT files were uploaded and classified using version 11b6 and 12.5 of the CNS tumor methylation classifier (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.molecularneuropathology.org/mnp/\u003c/span\u003e\u003cspan address=\"https://www.molecularneuropathology.org/mnp/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). A calibrated score cutoff of 0.9 was used to determine a successful diagnosis. Copy number variation (CNV) profiles were inferred using the R \u0026ldquo;conumee\u0026rdquo; package (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://bioconductor.org/packages/conumee/\u003c/span\u003e\u003cspan address=\"http://bioconductor.org/packages/conumee/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) as implemented in the classifier package.\u003c/p\u003e \u003cp\u003e \u003cem\u003eStatistical analysis.\u003c/em\u003e Analysis of correlation between genotype and occurrence of brain tumors in patients with NS was performed by comparing patients\u0026rsquo; germline findings in the current study with previously published data using its 95% confidence interval (CI) [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e].\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003ePatient Demographics and Clinical Outcomes\u003c/h2\u003e \u003cp\u003eTwenty-four patients were enrolled in this study, 19 (79%) of which were male. Twenty-two patients were younger than 18 years when diagnosed with CNS cancer. Clinical diagnoses consisted of NS (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;19; 79%), cardiofaciocutaneous (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2), Legius, linear nevus sebaceous (LNS), and NS with multiple lentigines syndrome in one patient each (\u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e). All patients had overt phenotypes associated with NNFRAS and were diagnosed before identification of CNS cancers. Five patients without symptoms attributable to CNS tumors were incidentally diagnosed with tumors during work-up for initiation of growth hormone supplementation (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2), seizures (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2, both with infra-tentorial tumors), or developmental delay (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;1). After a median follow-up of 7.5 years (range: 0.5\u0026ndash;20.2+), one patient with a low-grade glioma died of tumor progression and 3 patients died of causes unrelated to tumor. Ten patients with LGGs received chemotherapy and/or targeted therapy and one with a high-grade glioma underwent local radiation therapy and chemotherapy. None of the patients with histologically confirmed or presumptive DNETs required anticancer therapy (\u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eGermline Genetic Characteristics\u003c/h3\u003e\n\u003cp\u003eMolecular germline analysis via WES of peripheral blood confirmed the diagnoses in 23 (96%) cases (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA) and was used to compare to WES performed from tumor tissue (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). Germline pathogenic, gain-of-function \u003cem\u003ePTPN11\u003c/em\u003e missense variants occurred in 17 (89%; 95% CI: 0.67\u0026ndash;0.99) patients with NS (\u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e, Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). The distribution of germline variants in \u003cem\u003ePTPN11\u003c/em\u003e is shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC. Two \u003cem\u003ePTPN11\u003c/em\u003e genotypes, NM_002834.5(\u003cem\u003ePTPN11\u003c/em\u003e):c.182A\u0026thinsp;\u0026gt;\u0026thinsp;G (p.Asp61Gly) and c.417G\u0026thinsp;\u0026gt;\u0026thinsp;T (p.Glu139Asp) were significantly overrepresented in our patients at a two-sided 0.05 significance level (\u003cb\u003eSupplemental Table\u0026nbsp;2\u003c/b\u003e). The second most common NNFRAS driver mutation was \u003cem\u003eRAF1\u003c/em\u003e (n\u0026thinsp;=\u0026thinsp;2, [Figure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD]). Interestingly, 12 (71%) patients with NS had germline \u003cem\u003eFGFR1\u003c/em\u003e genetic abnormalities, including two with \u003cem\u003eFGFR1\u003c/em\u003e and \u003cem\u003ePIK3CA\u003c/em\u003e abnormalities and one with \u003cem\u003eFGFR1\u003c/em\u003e and \u003cem\u003ePIK3R1\u003c/em\u003e abnormalities (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e\n\u003ch3\u003eGenetic and Transcriptomic Characterization of Tumor Specimens\u003c/h3\u003e\n\u003cp\u003eTo better understand the genetic alterations associated with NS and CNS cancers, we performed WES from FFPE tumor specimens. WES was completed in 15 tumors from 13 (81%) of 16 patients with \u003cem\u003ePTPN11\u003c/em\u003e-associated NS and a confirmed or suspected LGG, including paired multifocal tumors in 2 patients. Fourteen (93%) of 15 tumors harbored a somatic heterozygous \u003cem\u003eFGFR1\u003c/em\u003e hotspot mutation or an internal tandem duplication (ITD) of its tyrosine kinase domain (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;1) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). While the cerebellar DNET of patient 14 harbored an \u003cem\u003eFGFR1\u003c/em\u003e ITD, his temporal DNET had an NM_023110.3(FGFR1):c.1966A\u0026thinsp;\u0026gt;\u0026thinsp;G (p.Lys656Glu). Patient 15 had an NM_023110.3(FGFR1):c.1638C\u0026thinsp;\u0026gt;\u0026thinsp;A (p.Asn546Lys) in his cerebellar and temporal DNETs, respectively.\u003c/p\u003e \u003cp\u003eTo identify splicing events and other alterations at the transcript level, RNA sequencing was performed on 12 tumors collected from 10 patients. An \u003cem\u003eFGFR1\u003c/em\u003e ITD was detected in one of patient 14\u0026rsquo;s tumors. No other transcript fusions were detected.\u003c/p\u003e\n\u003ch3\u003eEpigenetic Characterization of Tumor Specimens\u003c/h3\u003e\n\u003cp\u003eWhole-genome bisulfite sequencing was performed on 15 tumors, leading to changes in diagnosis for two patients. Patient 3 likely had a diffuse midline glioma, H3 K27M-mutant with \u003cem\u003eCDK4\u003c/em\u003e and \u003cem\u003eMDM2\u003c/em\u003e amplification (calibrated score of 0.87). Despite histological diagnosis of pilocytic astrocytoma, DNA methylation clustered patient 24\u0026rsquo;s tumor with rosette-forming glioneuronal tumors (calibrated score of 0.99). A summary of DNA methylation results is provided in \u003cb\u003eSupplemental Table\u0026nbsp;3\u003c/b\u003e.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eCentral Radiological Review and Histological Characteristics\u003c/h2\u003e \u003cp\u003eDetailed radiological data for all cases are provided in \u003cb\u003eSupplemental Table\u0026nbsp;4\u003c/b\u003e. Primary tumor site was in the infra-tentorial space (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;9), cerebral cortex (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8), diencephalon (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;3), optic pathway (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2), and spinal cord (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;1). Patient 14 had two separate synchronous tumors of equal size in the temporal lobe and cerebellum at diagnosis (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e) [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Nineteen patients underwent histological tumor confirmation, and five of six asymptomatic cases were diagnosed based on imaging only.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTwelve (52%) of 23 evaluable patients, including 9 (47%) with NS, displayed multiple T\u003csub\u003e2\u003c/sub\u003e/fluid-attenuated inversion recovery (FLAIR) hyperintense, non-infiltrative, mostly non-enhancing and cystic, separate lesions deep in brain parenchyma without mass effect (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u003cb\u003eand Supplemental Table\u0026nbsp;4\u003c/b\u003e). Institutional radiological review had already prospectively detected multiple brain lesions in at least 9 cases. Two patients with NS (patients 14 and 15) underwent resection of two separate synchronous and metachronous tumors, respectively, in the temporal lobe and cerebellum (\u003cb\u003eSupplemental Table\u0026nbsp;4\u003c/b\u003e). Among 10 patients without histological confirmation of distant parenchymatous lesions, a multifocal neoplastic process was confirmed based on slow radiological progression over a median of 6.6 years (range, 2.5\u0026thinsp;+\u0026thinsp;to 20.2+) in 8 patients with NNFRAS, 6 of them with NS (\u003cb\u003eSupplemental Table\u0026nbsp;4\u003c/b\u003e). Two patients had non-progressive multifocal distant tumors suspicious for a neoplastic process since they either shared imaging characteristics with the primary site (FLAIR ring sign [patient 9, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e]) or displayed mass effect with elevated choline and decreased N-acetylaspartate (NAA) on MR spectroscopy (patient 21)[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Multifocal brain lesions affected the posterior fossa (cerebellum and/or brainstem) and thalamus in 9 (100%) and 5 (56%) patients with NS, respectively, which are unusual locations considering their confirmed (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;5) or presumptive (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2) diagnosis of dysembryoplastic neuroepithelial tumor (DNET). Five patients experienced intra-tumoral hemorrhage with or without intra-ventricular spread before diagnosis, including both patients with multifocal, histologically confirmed tumors (\u003cb\u003eSupplemental Table\u0026nbsp;4\u003c/b\u003e). Excluding one participant with a diffuse leptomeningeal glioneuronal tumor (DLGNT), which almost uniformly presents with metastatic disease [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e], five patients developed leptomeningeal tumor spread at follow-up confirmed radiologically only, including patient 9 who had a DNET and slowly progressive arachnoid disease (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAccording to institutional histological review, diagnoses were pilocytic/pilomyxoid astrocytoma (WHO grade 1; \u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;9 [47%]), DNET (WHO grade 1; \u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;6 [32%]), and one each of LGG not otherwise specified (NOS; WHO grade 1), high-grade glioma NOS, schwannoma (WHO grade 1), and DLGNT (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). DNETs were diagnosed in both patients with histologically confirmed multifocal tumors. Central histological review of these 19 cases was not performed.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eOur work provides the first large-scale clinical, radiological, and molecular study evaluating NS-associated brain neoplasms, which were mostly LGGs. There was an overwhelming male predominance observed in NS (79%), similar to previously published case reports (61%; \u003cb\u003eSupplemental Table\u0026nbsp;5\u003c/b\u003e) [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan additionalcitationids=\"CR10 CR11 CR12 CR13 CR14 CR15 CR16 CR17 CR18 CR19\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e], for which this sex bias remains unknown. Brain tumors developed during childhood in most patients with NS and their continued slow growth during adulthood was documented in several cases. Further work is warranted to determine the behavior and repercussions of NS-associated brain tumors in adults.\u003c/p\u003e \u003cp\u003eThe prevalence of germline \u003cem\u003ePTPN11\u003c/em\u003e variants in NS is approximately 45% [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. Herein, we demonstrated an overrepresentation of germline \u003cem\u003ePTPN11\u003c/em\u003e and a genotype-phenotype association between NM_002834.5(PTPN11):c.182A\u0026thinsp;\u0026gt;\u0026thinsp;G (p.Asp61Gly) or c.417G\u0026thinsp;\u0026gt;\u0026thinsp;T (p.Glu139Asp) and the development of brain tumors in patients with NS. These \u003cem\u003ePTPN11\u003c/em\u003e variants, as well as others, are known to induce protein changes and activate mitogen-activated pathway kinase (MAPK) signaling [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Additionally, we discovered a 93% co-occurrence rate of somatic \u003cem\u003eFGFR1\u003c/em\u003e abnormalities and \u003cem\u003ePTPN11\u003c/em\u003e germline variants in patients with NS and LGG. A previously reported \u003cem\u003ein vitro\u003c/em\u003e cooperative effect of abnormalities in both genes was shown to cause overexpression of pERK compared to \u003cem\u003ePTPN11\u003c/em\u003e variants alone in murine fibroblasts and was implicated in the tumorigenesis of pilocytic astrocytomas [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. Similarly, a recent analysis of FGFR alterations across gliomas, including pediatric gliomas, support the hypothesis of a synergistic effect of PTPN11 and FGFR1 in the genesis of gliomas [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. We propose that cooperative interaction between \u003cem\u003ePTPN11\u003c/em\u003e and \u003cem\u003eFGFR1\u003c/em\u003e abnormalities is critical for the tumorigenesis of LGGs in patients with NS, including DNETs. This has potential practical implications for patients with NS, as FGFR1 inhibitors have shown preliminary activity in LGGs harboring \u003cem\u003eFGFR1\u003c/em\u003e variants [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. Likewise, other inhibitors of the MAPK pathway (e.g., MEK inhibitors) may represent alternative therapies for patients with NS and LGG.\u003c/p\u003e \u003cp\u003eMultiple case reports described the presence of separate parenchymal lesions in patients with NS and NNFRAS [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e], but only a few patients underwent histological confirmation [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e, \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. Here, we show that multifocal parenchymal lesions in NS unequivocally represent synchronous or metachronous LGGs based on histological confirmation (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2; 22%), slow growth documented over a median follow-up of 6.6 years (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;6; 67%), or typical radiological characteristics (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;1, 11%). The only patient with NS without histological confirmation or radiological disease progression harbored a synchronous satellite lesion located in the cerebellum with FLAIR hyperintense ring sign, similar to the primary tumor, which is suggestive of DNETs [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Although this case was previously reported, no details about radiological findings had been provided [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. The prevalence of multifocal tumors in 9 (53%) of 17 patients with NS and LGGs, a rate at least twice higher than those for patients with NF1 based on imaging [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e], is striking and warrants confirmation in larger studies. Unlike NF1, only two (11%) of our patients with NS had primary involvement of the optic pathway [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e], which further corroborates the distinct biological, clinical, and radiological tumor characteristics in patients with NS.\u003c/p\u003e \u003cp\u003eDNETs and other low-grade glioneuronal tumors accounted for approximately 50% of all CNS tumors in patients with NS and other NNFRAS reported to date [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e] (\u003cb\u003eSupplemental Table\u0026nbsp;5\u003c/b\u003e). Likewise, DNETs were overrepresented and commonly displayed multifocal involvement in our patients, an otherwise rare phenomenon [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. Therefore, the diagnosis of NS or other NNFRAS should be investigated in patients suspected to harbor multifocal LGGs. Based on a previous report [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e], it is possible that individuals with NS and other NNFRAS could have histologically distinct multifocal LGGs. We also report a few unique cases, including the first association of Legius syndrome with a CNS cancer and a second case of a presumed brain tumor in a child with cardiofaciocutaneous syndrome. Unfortunately, no tumor tissue was available in either patient for molecular analysis.\u003c/p\u003e \u003cp\u003eAlthough most patients did not require anticancer therapy beyond surgery, 7 (41%) of 17 patients with NS and a confirmed or presumptive LGG required standard chemotherapy and/or targeted agents, 5 of whom %) received at least 2 different regimens. Overall, NS-associated CNS tumors are mostly non-life-threatening LGGs with indolent growth, but may present with complications, including disease progression, leptomeningeal spread, significant morbidity, and even death despite aggressive therapy.\u003c/p\u003e \u003cp\u003eOne limitation of this study is its mostly retrospective design. Although 7 patients had been included in other reports [\u003cspan additionalcitationids=\"CR10\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e], we generated extensive new clinical, radiological, and molecular data about them. Based on the patients\u0026rsquo; overt presentation of NS and NNFRAS, our findings may not be applicable to those with subtle features who are diagnosed based on molecular screening after the diagnosis of CNS tumors [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn conclusion, patients with NS and germline \u003cem\u003ePTPN11\u003c/em\u003e variants account for nearly all individuals with NNFRAS and brain tumors in this study. Although approximately half of these patients harbored multifocal LGGs, their prognosis was good. However, anticancer therapy is required in a substantial minority of patients, particularly those with DNETs. Our finding that 93% of patients with NS and LGG harbor \u003cem\u003eFGFR1\u003c/em\u003e mutations provides an exciting new therapeutic opportunity for these patients. Further investigation with CNS imaging is recommended for patients with NNFRAS presenting with neurologic signs and/or symptoms. Screening of asymptomatic patients with NM_002834.5(PTPN11):c.182A\u0026thinsp;\u0026gt;\u0026thinsp;G (p.Asp61Gly) or c.417G\u0026thinsp;\u0026gt;\u0026thinsp;T (p.Glu139Asp) variants for brain tumors may also be considered.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eConflict of Interest:\u003c/h2\u003e \u003cp\u003eThe authors declare no conflict of interest relevant to this work.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding:\u003c/h2\u003e \u003cp\u003e This work was supported in part by funds provided by the Wheeler family, the Haley Weiss Memorial Fund, and by a P30CA047904 award to the UPMC Hillman Cancer Center Core Laboratory\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eAccess to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis: G.K. and A.B. Concept and design: G.K. and A.B. Recruitment of study participants : L.M.H., A.E.B., K.W.G., A.W.W., J.R.H., A.A.S, and A.B. Central radiologic review : A.B. Generation of molecular data : G.K. and A.B. Analysis of molecular data : S.R., R.S., J.M.S., U.T., and C.E.H. Statistical analysis : H.W. Writing of the manuscript at draft and any revision stages, and approval of its final version : G.K., S.R., S.E.G, L.M.H., R.S., A.E.B., K.W.G., A.W.W., J.R.H., A.A.S., H.W., J.M.S., U.T., C.E.H., and A.B.\u003c/p\u003e\u003ch2\u003eAcknowledgement\u003c/h2\u003e\u003cp\u003eWe thank Maureen Lyons for expertise in performing molecular studies, Dr. Marina N. Nikifirova and Dr. Abigail I. Wald for assisting with DNA methylation profiling, and Beth Stronach and Amanda Brown (Noonan Syndrome Foundation) for helping several patient families volunteer for study participation. We are indebted to the patients and their families for their willingness to participate in this study.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eDeidentified whole exome sequencing, RNA sequencing, and DNA methylation sequencing data will be deposited to GEO or EGA and made freely available.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eFiala EM, Jayakumaran G, Mauguen A, Kennedy JA, Bouvier N, Kemel Y, Fleischut MH, Maio A, Salo-Mullen EE, Sheehan M, Arnold AG, Latham A, Carlo MI, Cadoo K, Murkherjee S, Slotkin EK, Trippett T, Glade Bender J, Meyers PA, Wexler L, Dela Cruz FS, Cheung NK, Basu E, Kentsis A, Ortiz M, Francis JH, Dunkel IJ, Khakoo Y, Gilheeney S, Farouk Sait S, Forlenza CJ, Sulis M, Karajannis M, Modak S, Gerstle JT, Heaton TE, Roberts S, Yang C, Jairam S, Vijai J, Topka S, Friedman DN, Stadler ZK, Robson M, Berger MF, Schultz N, Ladanyi M, O\u0026apos;Reilly RJ, Abramson DH, Ceyhan-Birsoy O, Zhang L, Mandelker D, Shukla NN, Kung AL, Offit K, Zehir A, Walsh MF (2021) Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nat Cancer 2: 357-365 doi:10.1038/s43018-021-00172-1\u003c/li\u003e\n\u003cli\u003eWong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, Barahona P, Wilkie EE, Sullivan P, Bowen-James R, Syed M, Martincorena I, Abascal F, Sherstyuk A, Bolanos NA, Baber J, Priestley P, Dolman MEM, Fleuren EDG, Gauthier ME, Mould EVA, Gayevskiy V, Gifford AJ, Grebert-Wade D, Strong PA, Manouvrier E, Warby M, Thomas DM, Kirk J, Tucker K, O\u0026apos;Brien T, Alvaro F, McCowage GB, Dalla-Pozza L, Gottardo NG, Tapp H, Wood P, Khaw SL, Hansford JR, Moore AS, Norris MD, Trahair TN, Lock RB, Tyrrell V, Haber M, Marshall GM, Ziegler DS, Ekert PG, Cowley MJ (2020) Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med 26: 1742-1753 doi:10.1038/s41591-020-1072-4\u003c/li\u003e\n\u003cli\u003eZhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR (2015) Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 373: 2336-2346 doi:10.1056/NEJMoa1508054\u003c/li\u003e\n\u003cli\u003eKratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS (2011) Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 157C: 83-89 doi:10.1002/ajmg.c.30300\u003c/li\u003e\n\u003cli\u003eKratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlhase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schluter G, Gencik M, Uberlacker B, Lissewski C, Schanze I, Greene MH, Spix C, Zenker M (2015) Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer 112: 1392-1397 doi:10.1038/bjc.2015.75\u003c/li\u003e\n\u003cli\u003eLin AL, Gutmann DH (2013) Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol 10: 616-624 doi:10.1038/nrclinonc.2013.144\u003c/li\u003e\n\u003cli\u003eDunnett-Kane V, Burkitt-Wright E, Blackhall FH, Malliri A, Evans DG, Lindsay CR (2020) Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. Ann Oncol 31: 873-883 doi:10.1016/j.annonc.2020.03.291\u003c/li\u003e\n\u003cli\u003eRoberts AE, Allanson JE, Tartaglia M, Gelb BD (2013) Noonan syndrome. Lancet 381: 333-342 doi:10.1016/S0140-6736(12)61023-X\u003c/li\u003e\n\u003cli\u003eChiang MC, McDowell MM, Weaver K, Broniscer A, Greene S (2019) Is Schimmelpenning Syndrome Associated with Intracranial Tumors? A Case Report. Pediatr Neurosurg 54: 201-206 doi:10.1159/000497149\u003c/li\u003e\n\u003cli\u003eDodgshun AJ, SantaCruz N, Hwang J, Ramkissoon SH, Malkin H, Bergthold G, Manley P, Chi S, MacGregor D, Goumnerova L, Sullivan M, Ligon K, Beroukhim R, Herrington B, Kieran MW, Hansford JR, Bandopadhayay P (2016) Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol 128: 293-302 doi:10.1007/s11060-016-2109-x\u003c/li\u003e\n\u003cli\u003eEl-Ayadi M, Ansari M, Kuhnol CD, Bendel A, Sturm D, Pietsch T, Kramm CM, von Bueren AO (2019) Occurrence of high-grade glioma in Noonan syndrome: Report of two cases. Pediatr Blood Cancer 66: e27625 doi:10.1002/pbc.27625\u003c/li\u003e\n\u003cli\u003eFryssira H, Leventopoulos G, Psoni S, Kitsiou-Tzeli S, Stavrianeas N, Kanavakis E (2008) Tumor development in three patients with Noonan syndrome. Eur J Pediatr 167: 1025-1031 doi:10.1007/s00431-007-0636-3\u003c/li\u003e\n\u003cli\u003eKarafin M, Jallo GI, Ayars M, Eberhart CG, Rodriguez FJ (2011) Rosette forming glioneuronal tumor in association with Noonan syndrome: pathobiological implications. Clin Neuropathol 30: 297-300 doi:10.5414/np300374\u003c/li\u003e\n\u003cli\u003eLin FY, Bergstrom K, Person R, Bavle A, Ballester LY, Scollon S, Raesz-Martinez R, Jea A, Birchansky S, Wheeler DA, Berg SL, Chintagumpala MM, Adesina AM, Eng C, Roy A, Plon SE, Parsons DW (2016) Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle. Cold Spring Harb Mol Case Stud 2: a001057 doi:10.1101/mcs.a001057\u003c/li\u003e\n\u003cli\u003eMartinelli S, Carta C, Flex E, Binni F, Cordisco EL, Moretti S, Puxeddu E, Tonacchera M, Pinchera A, McDowell HP, Dominici C, Rosolen A, Di Rocco C, Riccardi R, Celli P, Picardo M, Genuardi M, Grammatico P, Sorcini M, Tartaglia M (2006) Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 166: 124-129 doi:10.1016/j.cancergencyto.2005.10.003\u003c/li\u003e\n\u003cli\u003eMcWilliams GD, SantaCruz K, Hart B, Clericuzio C (2016) Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy. Am J Med Genet A 170A: 195-201 doi:10.1002/ajmg.a.37379\u003c/li\u003e\n\u003cli\u003eShatara M, Schieffer KM, Melas M, Varga EA, Thomas D, Bucknor BA, Costello HM, Wheeler G, Kelly BJ, Miller KE, Rodriguez DP, Mathew MT, Lee K, Crotty E, Leary S, Paulson VA, Cole B, Abdelbaki MS, Finlay JL, Lazow MA, Salloum R, Fouladi M, Boue DR, Mardis ER, Cottrell CE (2024) Molecular characterization of gliomas and glioneuronal tumors amid Noonan syndrome: cancer predisposition examined. Front Oncol 14: 1453309 doi:10.3389/fonc.2024.1453309\u003c/li\u003e\n\u003cli\u003eSherman CB, Ali-Nazir A, Gonzales-Gomez I, Finlay JL, Dhall G (2009) Primary mixed glioneuronal tumor of the central nervous system in a patient with noonan syndrome: a case report and review of the literature. J Pediatr Hematol Oncol 31: 61-64 doi:10.1097/MPH.0b013e31818ab2cf\u003c/li\u003e\n\u003cli\u003eSiegfried A, Cances C, Denuelle M, Loukh N, Tauber M, Cave H, Delisle MB (2017) Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature. Am J Med Genet A 173: 1061-1065 doi:10.1002/ajmg.a.38108\u003c/li\u003e\n\u003cli\u003eSievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wefers AK, Reinhardt A, Coras R, Ruf VC, Schmid S, de Stricker K, Boldt HB, Kristensen BW, Petersen JK, Ulhoi BP, Gardberg M, Aronica E, Hasselblatt M, Bruck W, Bielle F, Mokhtari K, Lhermitte B, Wick W, Herold-Mende C, Hanggi D, Brandner S, Giangaspero F, Capper D, Rushing E, Wesseling P, Pfister SM, Figarella-Branger D, von Deimling A, Sahm F, Jones DTW (2019) Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathol 138: 497-504 doi:10.1007/s00401-019-02038-4\u003c/li\u003e\n\u003cli\u003eValera ET, McConechy MK, Gayden T, Rivera B, Jones DTW, Wittmann A, Han H, Bareke E, Nikbakht H, Mikael L, Queiroz RG, Suazo VK, Phi JH, Kim SK, Park SH, Fukaya R, Yum MS, Ko TS, de Oliveira RS, Machado HR, Brassesco MS, do Santos AC, Simao GN, Ramalho LNZ, Neder L, Scrideli CA, Tone LG, Majewski J, Jabado N (2018) Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. Acta Neuropathol 136: 657-660 doi:10.1007/s00401-018-1898-8\u003c/li\u003e\n\u003cli\u003eRyall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Gilheeney S, Rosenblum M, Bale T, Tsang DS, Laperriere N, Kulkarni A, Ibrahim GM, Drake J, Dirks P, Taylor MD, Rutka JT, Laughlin S, Shroff M, Shago M, Hazrati LN, D\u0026apos;Arcy C, Ramaswamy V, Bartels U, Huang A, Bouffet E, Karajannis MA, Santi M, Ellison DW, Tabori U, Hawkins C (2020) Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 37: 569-583 e565 doi:10.1016/j.ccell.2020.03.011\u003c/li\u003e\n\u003cli\u003eMehrad M, LaFramboise WA, Lyons MA, Trejo Bittar HE, Yousem SA (2018) Whole-exome sequencing identifies unique mutations and copy number losses in calcifying fibrous tumor of the pleura: report of 3 cases and review of the literature. Hum Pathol 78: 36-43 doi:10.1016/j.humpath.2018.04.005\u003c/li\u003e\n\u003cli\u003eBolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30: 2114-2120 doi:10.1093/bioinformatics/btu170\u003c/li\u003e\n\u003cli\u003eLi H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595 doi:10.1093/bioinformatics/btp698\u003c/li\u003e\n\u003cli\u003eVan der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S, DePristo MA (2013) From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics 43: 11 10 11-11 10 33 doi:10.1002/0471250953.bi1110s43\u003c/li\u003e\n\u003cli\u003eCibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31: 213-219 doi:10.1038/nbt.2514\u003c/li\u003e\n\u003cli\u003eAdzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249 doi:10.1038/nmeth0410-248\u003c/li\u003e\n\u003cli\u003eVaser R, Adusumalli S, Leng SN, Sikic M, Ng PC (2016) SIFT missense predictions for genomes. Nat Protoc 11: 1-9 doi:10.1038/nprot.2015.123\u003c/li\u003e\n\u003cli\u003eShihab HA, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR (2014) Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. Hum Genomics 8: 11 doi:10.1186/1479-7364-8-11\u003c/li\u003e\n\u003cli\u003eCingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6: 80-92 doi:10.4161/fly.19695\u003c/li\u003e\n\u003cli\u003eKarczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O\u0026apos;Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Genome Aggregation Database C, Neale BM, Daly MJ, MacArthur DG (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581: 434-443 doi:10.1038/s41586-020-2308-7\u003c/li\u003e\n\u003cli\u003eTalevich E, Shain AH, Botton T, Bastian BC (2016) CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 12: e1004873 doi:10.1371/journal.pcbi.1004873\u003c/li\u003e\n\u003cli\u003eBourgey M, Dali R, Eveleigh R, Chen KC, Letourneau L, Fillon J, Michaud M, Caron M, Sandoval J, Lefebvre F, Leveque G, Mercier E, Bujold D, Marquis P, Van PT, Anderson de Lima Morais D, Tremblay J, Shao X, Henrion E, Gonzalez E, Quirion PO, Caron B, Bourque G (2019) GenPipes: an open-source framework for distributed and scalable genomic analyses. Gigascience 8 doi:10.1093/gigascience/giz037\u003c/li\u003e\n\u003cli\u003eDobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21 doi:10.1093/bioinformatics/bts635\u003c/li\u003e\n\u003cli\u003eApostolides M, Li M, Arnoldo A, Ku M, Husic M, Ramani AK, Brudno M, Turinsky A, Hawkins C, Siddaway R (2023) Clinical Implementation of MetaFusion for Accurate Cancer-Driving Fusion Detection from RNA Sequencing. J Mol Diagn 25: 921-931 doi:10.1016/j.jmoldx.2023.09.002\u003c/li\u003e\n\u003cli\u003eTian L, Li Y, Edmonson MN, Zhou X, Newman S, McLeod C, Thrasher A, Liu Y, Tang B, Rusch MC, Easton J, Ma J, Davis E, Trull A, Michael JR, Szlachta K, Mullighan C, Baker SJ, Downing JR, Ellison DW, Zhang J (2020) CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. Genome Biol 21: 126 doi:10.1186/s13059-020-02043-x\u003c/li\u003e\n\u003cli\u003eTartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt I, Palleschi A, Petrucci TC, Sorcini M, Schoch C, Foa R, Emanuel PD, Gelb BD (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78: 279-290 doi:10.1086/499925\u003c/li\u003e\n\u003cli\u003eParmar HA, Hawkins C, Ozelame R, Chuang S, Rutka J, Blaser S (2007) Fluid-attenuated inversion recovery ring sign as a marker of dysembryoplastic neuroepithelial tumors. J Comput Assist Tomogr 31: 348-353 doi:10.1097/01.rct.0000243453.33610.9d\u003c/li\u003e\n\u003cli\u003eTartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70: 1555-1563 doi:10.1086/340847\u003c/li\u003e\n\u003cli\u003eJones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stutz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM, International Cancer Genome Consortium PedBrain Tumor P (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45: 927-932 doi:10.1038/ng.2682\u003c/li\u003e\n\u003cli\u003eApfelbaum AA, Morin E, Sturm D, Ayoub G, DiGiacomo J, Bahadur S, Chandarana B, Power PC, Cusick MM, Novikov D, Prabhakar P, Jones RE, Vogelzang J, Bossi CC, Malinowski S, Woodward LM, Jones TA, Jeang J, Lamson SW, Collins J, Cai KY, Jones JS, Oh S, Jeon H, Wang J, Cameron A, Rechter P, De Leon A, Murugesan K, Montesion M, Albacker LA, Ramkissoon SH, van Tilburg CM, Hardin EC, Sievers P, Sahm F, Yeo KK, Rosenberg T, Chi SN, Wright KD, Hebert S, Peck S, Picca A, Larouche V, Renzi S, Buhrlage SJ, Bale TA, Smith AA, Touat M, Jabado N, Fischer ES, Eck MJ, Baird L, Witt O, Kleinman CL, Nguyen QD, Sheer D, Alexandrescu S, Jones DTW, Ligon KL, Bandopadhayay P (2025) A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. Nat Commun 16: 7018 doi:10.1038/s41467-025-61820-z\u003c/li\u003e\n\u003cli\u003ePant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y, Investigators R (2023) Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 24: 925-935 doi:10.1016/S1470-2045(23)00275-9\u003c/li\u003e\n\u003cli\u003eLodi M, Boccuto L, Carai A, Cacchione A, Miele E, Colafati GS, Diomedi Camassei F, De Palma L, De Benedictis A, Ferretti E, Catanzaro G, Po A, De Luca A, Rinelli M, Lepri FR, Agolini E, Tartaglia M, Locatelli F, Mastronuzzi A (2020) Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature. Diagnostics (Basel) 10 doi:10.3390/diagnostics10080582\u003c/li\u003e\n\u003cli\u003eTuohy K, Lane J, Abendroth C, Iantosca M (2022) A Constellation of Atypical Findings in a Nine-Year-Old Child With Dysembryoplastic Neuroepithelial Tumors: A Case Report and Review of the Literature. Cureus 14: e27707 doi:10.7759/cureus.27707\u003c/li\u003e\n\u003cli\u003eBangalore Krishna K, Pagan P, Escobar O, Popovic J (2017) Occurrence of Cranial Neoplasms in Pediatric Patients with Noonan Syndrome Receiving Growth Hormone: Is Screening with Brain MRI prior to Initiation of Growth Hormone Indicated? Horm Res Paediatr 88: 423-426 doi:10.1159/000479107\u003c/li\u003e\n\u003cli\u003eGuillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P, Reseau NFF (2003) Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126: 152-160 doi:10.1093/brain/awg016\u003c/li\u003e\n\u003cli\u003eSanford RA, Bowman R, Tomita T, De Leon G, Palka P (1999) A 16-year-old male with Noonan\u0026apos;s syndrome develops progressive scoliosis and deteriorating gait. Pediatr Neurosurg 30: 47-52 doi:10.1159/000028761\u003c/li\u003e\n\u003cli\u003eLellouch-Tubiana A, Bourgeois M, Vekemans M, Robain O (1995) Dysembryoplastic neuroepithelial tumors in two children with neurofibromatosis type 1. Acta Neuropathol 90: 319-322 doi:10.1007/BF00296517\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Table","content":"\u003cp\u003eTable 1 is available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"journal-of-neuro-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"neon","sideBox":"Learn more about [Journal of Neuro-Oncology](https://www.springer.com/journal/11060)","snPcode":"11060","submissionUrl":"https://submission.nature.com/new-submission/11060/3","title":"Journal of Neuro-Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Brain tumor, glioma, Noonan syndrome, PTPN11, FGFR1","lastPublishedDoi":"10.21203/rs.3.rs-8662616/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8662616/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003ePurpose: \u003c/strong\u003eTo characterize the clinical, radiological, and molecular characteristics of CNS tumors associated with Noonan syndrome (NS) and other non-Neurofibromatosis type 1 RASopathies.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods:\u003c/strong\u003e Twenty-four patients with concern for NS underwent clinical and central radiological review in this multi-institutional study. Whole-exome sequencing, RNA sequencing, and methylation analyses of peripheral blood and/or tumor specimens were performed.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eNineteen (79%) of 24 participants had NS, 17/19 (89%) of which had a germline \u003cem\u003ePTPN11\u003c/em\u003e variant; Nineteen of 24 participants (79%) were male. Seventeen (89%) patients with NS developed CNS cancers, including low-grade glioma, (LGG; pure pilocytic/pilomyxoid astrocytoma; \u003cem\u003en\u003c/em\u003e=9) and mixed dysembryoplastic neuroepithelial tumor (DNET; \u003cem\u003en\u003c/em\u003e=6). Five patients incidentally diagnosed did not undergo histological confirmation. Radiological review showed multifocal parenchymal tumors in 9 patients with NS, including histologically confirmed neoplasm (\u003cem\u003en\u003c/em\u003e=2), radiologic progression (\u003cem\u003en\u003c/em\u003e=6), or typical tumoral imaging (\u003cem\u003en\u003c/em\u003e=1). All LGGs in patients with NS and germline \u003cem\u003ePTPN11\u003c/em\u003e variants except one (14/15; 93%) harbored somatic \u003cem\u003eFGFR1\u003c/em\u003e abnormalities. RNA sequencing of 12 tumors detected \u003cem\u003eFGFR1\u003c/em\u003e internal tandem duplication in one patient. Comparison with published data showed a statistically significant association between brain tumor occurrence and \u003cem\u003ePTPN11\u003c/em\u003e-related NS, driven by two genotypes: NM_002834.5(PTPN11):c.182A\u0026gt;G (p.Asp61Gly) and c.417G\u0026gt;T (p.Glu139Asp). Ten patients with LGGs, including 7 (41%) with NS, required chemotherapy. After median follow-up of 7.5 years, one patient died of CNS cancer.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e \u003cem\u003ePTPN11\u003c/em\u003e-related NS predisposes to multifocal pure and mixed LGGs confirmed by radiological, histological, and molecular characteristics. Targeting FGFR1-related pathways may provide new treatment approaches for patients with NS and LGGs.\u003c/p\u003e","manuscriptTitle":"PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-28 03:05:59","doi":"10.21203/rs.3.rs-8662616/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-02-06T12:15:21+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-02-06T02:33:15+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-02-05T21:36:11+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-02-05T05:15:47+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-01-28T15:10:18+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"37305562969054884833571001291927855906","date":"2026-01-28T13:37:30+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"236034902231784044241533466983679540139","date":"2026-01-27T22:22:23+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"31238893316179849991086767922864734900","date":"2026-01-26T21:05:52+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-01-25T22:13:08+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"260706601807468805716915640002620391950","date":"2026-01-22T14:46:35+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"44223640337059197660317133441491357561","date":"2026-01-22T14:12:13+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-01-22T11:27:01+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-01-22T05:48:04+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2026-01-22T05:44:01+00:00","index":"","fulltext":""},{"type":"submitted","content":"Journal of Neuro-Oncology","date":"2026-01-21T17:45:07+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"journal-of-neuro-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"neon","sideBox":"Learn more about [Journal of Neuro-Oncology](https://www.springer.com/journal/11060)","snPcode":"11060","submissionUrl":"https://submission.nature.com/new-submission/11060/3","title":"Journal of Neuro-Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"ec3ae1bf-87fd-4292-a2ca-9ccf17ee938c","owner":[],"postedDate":"January 28th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-03-09T16:10:07+00:00","versionOfRecord":{"articleIdentity":"rs-8662616","link":"https://doi.org/10.1007/s11060-026-05478-7","journal":{"identity":"journal-of-neuro-oncology","isVorOnly":false,"title":"Journal of Neuro-Oncology"},"publishedOn":"2026-03-05 15:58:55","publishedOnDateReadable":"March 5th, 2026"},"versionCreatedAt":"2026-01-28 03:05:59","video":"","vorDoi":"10.1007/s11060-026-05478-7","vorDoiUrl":"https://doi.org/10.1007/s11060-026-05478-7","workflowStages":[]},"version":"v1","identity":"rs-8662616","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8662616","identity":"rs-8662616","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}